📰 Alkermes News
Page 33 - Alkermes News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alkermes. Real-time updates on events, politics, business and more.
June 7, 2023
Goldman Sachs analyst Chris Shibutani reiterated a Buy rating on Alkermes (ALKS – Research Report) today. The company’s shares close...
June 7, 2023
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of $40.00. ...
June 7, 2023
Alkermes plc (NASDAQ:ALKS – Get Rating) Director Cato T. Laurencin sold 2,800 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $31.50, for a total transaction of $88,200.00. Following the completion of the transaction, the director now directly owns 7,479 shares […]
June 6, 2023
CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.In contrast to prior findings in melanoma, no biomarkers appeared prognostic for RFS among patients who received placebo.
June 6, 2023
The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.
June 6, 2023
The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.
June 6, 2023
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the...
June 6, 2023
NEW BRUNSWICK (dpa-AFX) - Biopharmaceutical company Alkermes plc (ALKS) on Tuesday raised its fiscal 2023 earnings and revenue forecast after it received a final award from the arbitral tribunal
June 5, 2023
Sarissa believes its nominees have experience and skills that the current board lacks Sarissa does not understand why the Alkermes independent directors refuse to add any Sarissa representatives
June 5, 2023
Sarissa believes its nominees have experience and skills that the current board lacks Sarissa does not understand why the Alkermes independent directors refuse to add any Sarissa representatives to... | June 5, 2023